# Christian Schütz > Christian Schütz is a seed investor at b2venture (Saint Gallen) backing Health Care and Medical. See 9 investments, check sizes, portfolio. Updated Aug 2026. - Type: Angel Investor - Fund: [b2venture](https://shizune.co/investors/profile/btovpartners) - Location: Saint Gallen, Switzerland - Total investments: 9 - Last investment: Jan 2025 - Lead investor: 56% - Last updated: Aug 2026 - LinkedIn: https://www.linkedin.com/in/christian-schuetz-50018a Christian Schütz is a seed investor at b2venture in Saint Gallen focused on Health Care and Medical. Christian Schütz is based out of Saint Gallen, Sankt Gallen and is the Partner of b2venture. Christian Schütz attended the EBS University of Business and Law. ## Investment focus ### Industry | Industry | Investments | Share | | --- | --- | --- | | Health Care | 2 | 22% | | Medical | 1 | 11% | | Consumer | 1 | 11% | | Hospital | 1 | 11% | | Software | 1 | 11% | 10 industries tracked in total. ### Stage | Stage | Investments | Share | | --- | --- | --- | | Seed | 2 | 22% | | Series A | 1 | 11% | | Series B | 1 | 11% | | Series C | 1 | 11% | | Series D | 1 | 11% | 7 stages tracked in total. ### Country | Country | Investments | Share | | --- | --- | --- | | Belgium | 1 | 11% | | United States | 1 | 11% | | United Kingdom | 1 | 11% | ## Investments | Company | Description | Amount | Stage | Date | Website | | --- | --- | --- | --- | --- | --- | | NOAT | We create tools that kill smoking. | $7M | Seed | Jan 01, 2025 | | | Quanta | Quanta is a medical devices company that develops advanced haemodialysis systems for use in the home and clinic. Quanta is focused on the commercialisation and ongoing development of SC+, an innovative cartridge-based haemodialysis system.SC+ is a high performance, compact haemodialysis system providing clinical efficacy by utilising typical flowrates of traditional in-centre machines.SC+ supports the entire ‘Continuum of Care’ for dialysis patients, from nurse-assisted treatment through self-care in centre to home haemodialysis. Their system facilitates the seamless transition between treatment modalities providing the best tool to enable flexibility for patients, and treatment options for physicians. | $60M | Series E | Nov 18, 2024 | | | Quanta | Quanta is a medical devices company that develops advanced haemodialysis systems for use in the home and clinic. Quanta is focused on the commercialisation and ongoing development of SC+, an innovative cartridge-based haemodialysis system.SC+ is a high performance, compact haemodialysis system providing clinical efficacy by utilising typical flowrates of traditional in-centre machines.SC+ supports the entire ‘Continuum of Care’ for dialysis patients, from nurse-assisted treatment through self-care in centre to home haemodialysis. Their system facilitates the seamless transition between treatment modalities providing the best tool to enable flexibility for patients, and treatment options for physicians. | $245M | Series D | Jun 23, 2021 | | | LynxCare | LynxCare is an AI-powered Big Data platform. We enable hospitals to mine their legacy data, to improve clinical efficiency and higher the quality of care. | $2M | | Jan 29, 2020 | | | LynxCare | LynxCare is an AI-powered Big Data platform. We enable hospitals to mine their legacy data, to improve clinical efficiency and higher the quality of care. | $2M | Seed | Jan 29, 2020 | | | LynxCare | LynxCare is an AI-powered Big Data platform. We enable hospitals to mine their legacy data, to improve clinical efficiency and higher the quality of care. | $2M | Seed | Jan 29, 2020 | | | Quanta | Quanta is a medical devices company that develops advanced haemodialysis systems for use in the home and clinic. Quanta is focused on the commercialisation and ongoing development of SC+, an innovative cartridge-based haemodialysis system.SC+ is a high performance, compact haemodialysis system providing clinical efficacy by utilising typical flowrates of traditional in-centre machines.SC+ supports the entire ‘Continuum of Care’ for dialysis patients, from nurse-assisted treatment through self-care in centre to home haemodialysis. Their system facilitates the seamless transition between treatment modalities providing the best tool to enable flexibility for patients, and treatment options for physicians. | $49.8M | Series C | Jul 29, 2019 | | | Quanta | Quanta is a medical devices company that develops advanced haemodialysis systems for use in the home and clinic. Quanta is focused on the commercialisation and ongoing development of SC+, an innovative cartridge-based haemodialysis system.SC+ is a high performance, compact haemodialysis system providing clinical efficacy by utilising typical flowrates of traditional in-centre machines.SC+ supports the entire ‘Continuum of Care’ for dialysis patients, from nurse-assisted treatment through self-care in centre to home haemodialysis. Their system facilitates the seamless transition between treatment modalities providing the best tool to enable flexibility for patients, and treatment options for physicians. | $35.4M | Series B | Nov 03, 2014 | | | Quanta | Quanta is a medical devices company that develops advanced haemodialysis systems for use in the home and clinic. Quanta is focused on the commercialisation and ongoing development of SC+, an innovative cartridge-based haemodialysis system.SC+ is a high performance, compact haemodialysis system providing clinical efficacy by utilising typical flowrates of traditional in-centre machines.SC+ supports the entire ‘Continuum of Care’ for dialysis patients, from nurse-assisted treatment through self-care in centre to home haemodialysis. Their system facilitates the seamless transition between treatment modalities providing the best tool to enable flexibility for patients, and treatment options for physicians. | $14.3M | Series A | Nov 01, 2009 | | 9 of 9 investments shown. ## Co-investors - [Seroba Life Sciences](https://shizune.co/investors/profile/seroba-life-sciences) — VC Fund, 4 deals together - [Wellington Partners](https://shizune.co/investors/profile/wellington-partners) — VC Fund, 4 deals together - [Alchemist Accelerator](https://shizune.co/investors/profile/alchemist-accelerator) — VC Fund, 3 deals together - [HERAN Partners](https://shizune.co/investors/profile/heran-partners) — VC Fund, 3 deals together - [Glenview Capital Management](https://shizune.co/investors/profile/glenview-capital-management) — VC Fund, 2 deals together - [NBGI Ventures](https://shizune.co/investors/profile/nbgi-ventures) — VC Fund, 2 deals together ## About b2venture VC Fund · Saint Gallen, Switzerland B2venture is a venture capital firm focused on early-stage investments in digital and industrial technology companies. B2venture invests EUR 100m+ per year in high-growth companies with ticket sizes from EUR 0.25m to 3.5m. 5 contacts available at b2venture. | Name | Title | Profile | | --- | --- | --- | | Andreas Goeldi | Partner | https://shizune.co/investors/profile/andreas-goeldi | | Christian Schütz | Partner | https://shizune.co/investors/profile/christian-schuetz | | Florian Schweitzer | Founding Partner | https://shizune.co/investors/profile/florian-schweitzer | | Jochen Gutbrod | Partner and Executive Chairman | https://shizune.co/investors/profile/dr-jochen-gutbrod | | Mathias Ockenfels | Partner | https://shizune.co/investors/profile/mathias-ockenfels | ## Similar investors ### Similar stage - [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund - [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund - [Right Side Capital Management](https://shizune.co/investors/profile/right-side-capital-management) — VC Fund ## FAQ ### What does Christian Schütz invest in? Christian Schütz invests primarily in Health Care, Medical and Consumer startups, most often at Seed and Series A stage. Most of the 9 investments tracked by Shizune back companies in Belgium. The Investment Focus section breaks down every industry, stage and country in the portfolio. ### When did Christian Schütz last invest? The most recent investment recorded for Christian Schütz closed in Jan 2025. Shizune tracks 9 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly. ### Is Shizune's investor data accurate? Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page. # About Shizune Shizune.co is an investor database. Core features: - 48,091 startup investors (angels, VCs, accelerators, and others) - Email, phone, LinkedIn (for intros), socials, and other contact data - Updated daily from public funding news - CSV and Excel export The User can access the full database FOR FREE after signing up: shizune.co